Last Price$567.0(1.1%)
Market Cap$207.3B
LTM Research & Development Expenses (R&D)
$1,145.3M
YoY Growth
+14.7%
3Y CAGR
+19.5%
5Y CAGR
+15.5%
Stock quality & Intrinsic value
7/10
81.3% overvalued
Intuitive Surgical, Inc. Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $17.4M | $29.8M | $48.9M | $79.4M | $95.1M | $116.0M | $140.2M | $170.0M | $167.7M | $178.0M | $197.4M | $239.6M | $328.6M | $418.1M | $557.3M | $595.1M | $671.0M | $879.0M | $998.8M | $1,145.3M |
Overvalued or undervalued?
Check the intrinsic value for ISRG
and see if it's the right time to invest.
Intuitive Surgical, Inc. (ISRG) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Intuitive Surgical, Inc.ISRG
$1,145.3M
14.7%
19.5%
15.5%
Median Peer Set
$292.6M
1.7%
8.7%
8.8%
Becton, Dickinson and CompanyBDX
$1,243.0M
2.4%
(3.0%)
3.0%
Alcon Inc.ALC
$876.0M
4.4%
1.3%
6.0%
Baxter International Inc.BAX
$673.0M
0.9%
8.0%
2.5%
AptarGroup, Inc.ATR
$440.6M
(22.1%)
1.9%
7.4%
ResMed Inc.RMD
$318.8M
4.8%
10.2%
10.1%
Hologic, Inc.HOLX
$266.3M
(7.0%)
(2.8%)
2.1%
Masimo CorporationMASI
$222.8M
27.2%
17.5%
19.0%
The Cooper Companies, Inc.COO
$155.1M
12.9%
18.7%
12.3%
West Pharmaceutical Services, Inc.WST
$69.1M
1.0%
9.4%
12.2%
Repligen CorporationRGEN
$41.8M
(4.0%)
9.5%
19.2%
ISRG key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 227.3 63.8% | 372.7 63.9% | 600.8 61.2% | 874.9 45.6% | 1,052.2 20.3% | 1,413.0 34.3% | 1,757.3 24.4% | 2,178.8 24.0% | 2,265.1 4.0% | 2,131.7 (5.9%) | 2,384.4 11.9% | 2,704.4 13.4% | 3,128.9 15.7% | 3,724.2 19.0% | 4,478.5 20.3% | 4,358.4 (2.7%) | 5,710.1 31.0% | 6,222.2 9.0% | 7,124.1 14.5% | 8,352.1 17.2% |
| Cost of Goods Sold (COGS) | 73.8 | 124.8 | 186.5 | 254.1 | 301.1 | 383.0 | 483.5 | 608.5 | 670.9 | 717.9 | 806.5 | 814.3 | 934.8 | 1,120.1 | 1,368.3 | 1,497.2 | 1,751.6 | 2,026.2 | 2,394.6 | 2,717.9 |
% margin | 153.6 67.6% | 247.8 66.5% | 414.3 69.0% | 620.8 71.0% | 751.1 71.4% | 1,030.0 72.9% | 1,273.8 72.5% | 1,570.3 72.1% | 1,594.2 70.4% | 1,413.8 66.3% | 1,577.9 66.2% | 1,890.1 69.9% | 2,194.1 70.1% | 2,604.1 69.9% | 3,110.2 69.4% | 2,861.2 65.6% | 3,958.5 69.3% | 4,196.0 67.4% | 4,729.5 66.4% | 5,634.2 67.5% |
| Operating Expenses | 84.8 | 140.5 | 207.5 | 309.9 | 373.6 | 474.8 | 579.0 | 692.2 | 741.7 | 869.0 | 837.9 | 944.9 | 1,139.5 | 1,404.7 | 1,735.7 | 1,811.4 | 2,137.5 | 2,618.9 | 2,962.7 | 3,285.3 |
| Research & Development Expenses (R&D) | 17.4 | 29.8 | 48.9 | 79.4 | 95.1 | 116.0 | 140.2 | 170.0 | 167.7 | 178.0 | 197.4 | 239.6 | 328.6 | 418.1 | 557.3 | 595.1 | 671.0 | 879.0 | 998.8 | 1,145.3 |
| Selling, General & Administrative Expenses (SG&A) | 67.4 | 110.7 | 158.7 | 230.6 | 278.5 | 358.8 | 438.8 | 522.2 | 574.0 | 691.0 | 640.5 | 705.3 | 810.9 | 986.6 | 1,178.4 | 1,216.3 | 1,466.5 | 1,739.9 | 1,963.9 | 2,140.0 |
% margin | 68.8 30.3% | 107.4 28.8% | 206.7 34.4% | 310.8 35.5% | 377.4 35.9% | 555.2 39.3% | 694.8 39.5% | 878.1 40.3% | 852.5 37.6% | 544.8 25.6% | 740.0 31.0% | 945.2 35.0% | 1,054.6 33.7% | 1,199.4 32.2% | 1,374.5 30.7% | 773.6 17.7% | 1,821.0 31.9% | 1,211.3 19.5% | 1,766.8 24.8% | 2,348.9 28.1% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 116.8 | 157.2 | 69.3 | 29.7 | 192.1 | 324.9 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 15.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 29.7 | 0.0 | 0.0 |
| Pre-tax Income | 73.8 | 120.1 | 237.2 | 335.2 | 396.1 | 572.3 | 709.7 | 893.9 | 870.9 | 549.0 | 758.5 | 980.8 | 1,096.5 | 1,279.5 | 1,502.2 | 1,207.0 | 1,890.3 | 1,606.8 | 1,958.9 | 2,673.8 |
% effective tax rate | (20.3) (27.5%) | 48.1 40.0% | 92.7 39.1% | 130.9 39.0% | 163.5 41.3% | 190.5 33.3% | 214.6 30.2% | 237.3 26.5% | 199.9 23.0% | 130.2 23.7% | 169.7 22.4% | 244.9 25.0% | 436.5 39.8% | 154.5 12.1% | 120.4 8.0% | 140.2 11.6% | 162.2 8.6% | 262.4 16.3% | 141.6 7.2% | 336.3 12.6% |
% margin | 94.1 41.4% | 72.0 19.3% | 144.5 24.1% | 204.3 23.4% | 232.6 22.1% | 381.8 27.0% | 495.1 28.2% | 656.6 30.1% | 671.0 29.6% | 418.8 19.6% | 588.8 24.7% | 735.9 27.2% | 660.0 21.1% | 1,127.9 30.3% | 1,379.3 30.8% | 1,060.6 24.3% | 1,704.6 29.9% | 1,322.3 21.3% | 1,798.0 25.2% | 2,322.6 27.8% |
| EPS | 0.30 | 0.22 | 0.42 | 0.58 | 0.67 | 1.08 | 1.40 | 1.83 | 1.86 | 1.26 | 1.76 | 2.13 | 1.97 | 3.31 | 3.98 | 3.02 | 4.79 | 3.72 | 5.12 | 6.54 |
| Diluted EPS | 0.28 | 0.21 | 0.41 | 0.57 | 0.66 | 1.05 | 1.37 | 1.78 | 1.86 | 1.23 | 1.73 | 2.08 | 1.89 | 3.16 | 3.85 | 2.94 | 4.66 | 3.65 | 5.03 | 6.42 |
% margin | 75.5 33.2% | 107.4 28.8% | 219.8 36.6% | 335.9 38.4% | 377.4 35.9% | 595.6 42.2% | 741.3 42.2% | 935.9 43.0% | 919.8 40.6% | 619.2 29.0% | 740.0 31.0% | 1,050.7 38.9% | 1,157.9 37.0% | 1,322.2 35.5% | 1,374.5 30.7% | 1,049.8 24.1% | 1,821.0 31.9% | 1,577.1 25.3% | 2,169.0 30.4% | 2,673.8 32.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Intuitive Surgical, Inc.'s Research & Development Expenses (R&D)?
As of today, Intuitive Surgical, Inc.'s last 12-month Research & Development Expenses (R&D) is $1,145.3M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Intuitive Surgical, Inc.'s Research & Development Expenses (R&D) growth rate?
Over the last year, Intuitive Surgical, Inc.'s Research & Development Expenses (R&D) growth was 14.7%. The average annual Research & Development Expenses (R&D) growth rates for Intuitive Surgical, Inc. have been 22.2% over the past three years, 15.5% over the past five years.
3) Is Intuitive Surgical, Inc.'s Research & Development Expenses (R&D) growth rate Good?
Over the last year, Intuitive Surgical, Inc.'s Research & Development Expenses (R&D) growth was 14.7%, which is higher than industry growth of 0.0%. It indicates that Intuitive Surgical, Inc.'s Research & Development Expenses (R&D) growth is Bad.